Bli medlem
Bli medlem

Du är här

2016-11-07

Molecular Health Unveils New Decision Support Solutions for Clinical Interpretation of Cancer Genome Data at AMP 2016 Annual Meeting

Molecular Health
Press release

Molecular Health Unveils New Decision Support Solutions for Clinical
Interpretation of Cancer Genome Data at AMP 2016 Annual Meeting

Molecular Health Guide(TM) Workbench Manager for comprehensive, end-to-end
clinical decision support

Molecular Health Guide(TM) Clinical Annotation Service for variant analysis and
interpretation

BOSTON and HEIDELBERG, Germany, Nov. 07, 2016 (GLOBE NEWSWIRE) -- Molecular
Health, a leader in decision support technology for precision medicine, today
announced the launch of its next-generation clinical decision support
solutions, Molecular Health GuideTM Workbench Manager and Molecular Health
Guide(TM) Clinical Annotation Service. These services are based on the
Company’s proprietary cloud-based software platform for the automated analysis,
clinical interpretation, and reporting of genetic alterations from
next-generation sequencing (NGS) performed by laboratories and hospitals.
Molecular Health will be showcasing the new Molecular Health GuideTM offerings,
initially provided in oncology, at Booth #1805 during the Association for
Molecular Pathology (AMP) 2016 Annual Meeting taking place November 10-12 at
the Charlotte Convention Center in North Carolina.

These new clinical decision support products are based on Molecular Health’s
DataomeTM technology, which focuses on the capture, integration, and analysis
of molecular outcomes data from patients that are mapped to expert-curated,
peer-reviewed, published biomedical literature. The curated databases include
clinical variant interpretations (CVIs) that are created by a rigorous process
that includes expert physician review.

Molecular Health GuideTM Workbench Manager delivers a comprehensive clinical
decision support service, from bioinformatics analysis of the NGS data from a
patient’s tumor to the generation of a custom report. Based upon the
identification of reportable variants, Workbench Manager generates a summary of
potentially effective treatment options, potentially ineffective treatment
options, and treatment options that may pose a higher risk of adverse
reactions. It also provides a matching tool for clinical trials. Workbench
Manager enables physicians and laboratories to reduce the time-consuming,
cost-intensive and error-prone process of manual variant interpretation by
providing clinical annotations and interpretations reviewed by expert molecular
pathologists and oncologists. Workbench Manager features a rich, interactive
user interface and digital workflow for those who want to create a high-quality
tailored report available in minutes.

Molecular Health GuideTM Clinical Annotation Service powers the automated
delivery of clinically-reviewed annotations for actionable variants. Within
minutes, Clinical Annotation Service delivers client customized
clinically-relevant data, including: clinical variant narratives,
evidence-based treatment options, matching trials, and other supplemental data
such as drug descriptions and relevant drug-drug interactions. The technology
is highly scalable and easily integrated into existing workflows, pipeline
management, and reporting systems for use by high-throughput laboratories and
other high-volume customers.

Les Paul, MD, MS, Chief Medical Officer and U.S. CEO, Molecular Health,
commented, “Molecular Health GuideTM clinical decision support solutions help
molecular pathologists and oncologists to more effectively manage molecular
information from Next-Generation Sequencing of patients’ tumors including the
identification of potentially effective or potentially ineffective treatment
and relevant clinical trials. We have designed these offerings to
strategically address the needs of oncologists and pathologists as well as
large laboratory, hospital, and research customers.”

Friedrich von Bohlen, Chief Executive Officer, Molecular Health, commented,
“Molecular Health is the leading precision medicine and clinical decision
support option for customers who want access to make more informed treatment
decisions. We developed both Molecular Health GuideTM offerings based on the
valuable input of the medical community and now we have a product that is
primed to improve patient care and outcomes by empowering the medical community
with access to real-time solutions which leverage the world’s healthcare data.
The breadth and quality of our contributions to the medical community are
exemplified with this product launch and our recent Clinical Laboratory
Improvement Amendments (CLIA) certification and College of American
Pathologists (CAP) accreditation for bioinformatics analysis, variant
annotation and interpretation. This launch executes on our mission to power the
future of precision medicine.”

Molecular Health GmbH is certified according to DIN EN ISO 13485 for the
design, development and manufacture of software systems for the integrated
analysis of clinical and genomic patient data to support treatment decisions
and provision of related services. In addition, Molecular Health is Clinical
Laboratory Improvement Amendments (CLIA) certified and accredited by the
College of American Pathologists (CAP) for bioinformatics analysis, variant
annotation and interpretation. This allows Molecular Health to provide its
bioinformatics analysis services to clinical laboratories in the United States
that are also accredited.

In the European Union, Molecular Health GuideTM is registered as an In Vitro
Diagnostic (IVD) device.

About Molecular Health

Molecular Health is a leading precision medicine informatics company that
leverages its proprietary cloud-based DataomeTMtechnology platform to provide a
comprehensive and disruptive healthcare decision engine. The DataomeTM
technology platform is the culmination of carefully curated and
medically-reviewed information from millions of scientific and medical
publications together with data from globally available databases of clinical
and molecular information. The platform is regularly updated and curated by
biomedical experts along strict processes, and has robust and expanding IP
protection. DataomeTM technology powers the Company’s Molecular Health GuideTM
service offerings.

Molecular Health GmbH is located in Heidelberg, Germany and its subsidiary,
Molecular Health, Inc., is located in Boston, Massachusetts, USA.

To learn more, please visit: www.molecularhealth.com.

Investors
Nick Laudico
The Ruth Group
(646) 536-7030
nlaudico@theruthgroup.com

Media
Kirsten Thomas / Chris Hippolyte
The Ruth Group
+1 508-280-6592 / +1 646-536-7023
kthomas@theruthgroup.com / chippolyte@theruthgroup.com

Författare SSE

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.